Krystal Biotech, Inc. (KRYS) Form 10-Q — Nov 2, 2026
Krystal Biotech reported Q3 2026 net product revenue of $127.3 million, up 30% year-over-year from $97.8 million, driven primarily by VYJUVEK launches in Europe and Japan. Nine-month revenue reached $362.9 million, up 29% from $282.0 million. Q3 net income was $63.1 million versus $79.4 million a year ago; the decline is due to a large one-time deferred tax asset valuation allowance release that boosted the prior-year quarter, not operational weakness. Income from operations rose 72% to $71.1 million, and gross margin held at 94%.
Key figures
- Eps
- 2.05
- Revenue
- 127341000
- Net Income
- 63068000
- Revenue Yoy
- 30%
- Total Assets
- 1586056000
- Cash Position
- 462841000
- Shares Outstanding
- 29633472
- Gross margin q3
- 94%
- Q3 2025 revenue
- 97800000
- Japan revenue q3
- 8762000
- Europe revenue q3
- 23256000
- Nine month revenue
- 362920000
- Buyback authorization
- 400000000
- Nine month net income
- 173768000
- Nine month eps diluted
- 5.66
- Operating cash flow 9m
- 246420000
- Cash plus short term investments
- 911900000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.